US Weekly IPO and SPAC Monitor: Lab-grown Diamond Producer Adamas One and BullFrog AI

No IPO’s priced during Thanksgiving week, though the one small deal scheduled to price, lab-grown diamond producer Adamas One (JEWL) may price this week, planning to raise $34 million. BullFrog AI Holdings (BFAI) also plans to raise $8 million. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors with the stock market surge this week. There are several large issuers in the pipeline. … Continue reading “US Weekly IPO and SPAC Monitor: Lab-grown Diamond Producer Adamas One and BullFrog AI”

US Weekly IPO and SPAC Monitor: Lab-grown Diamond Producer Adamas One

There is just one small deal scheduled to price, lab-grown diamond producer Adamas One (JEWL) in the short Thanksgiving week. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors with the stock market surge this week. There are several large issuers in the pipeline, as well as sizable new filings from insurer Skyward Specialty (SKWD) and oil and gas companies TXO Energy Partners (TXO) and BKV Corp (BKV), … Continue reading “US Weekly IPO and SPAC Monitor: Lab-grown Diamond Producer Adamas One”

US Weekly IPO and SPAC Monitor: BullFrog AI and Acrivon Therapeutics

There is just one small deal scheduled to price, Nano-cap BullFrog AI Holdings (BFAI) is developing an analytical AI/ML platform for drug development. Precision oncology biotech Acrivon Therapeutics (ACRV) may also price, after delaying its $100 million IPO. Last week we were surprised by holdover IPOs and one, Intensity Therapeutics (INTS) postponed. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors with the … Continue reading “US Weekly IPO and SPAC Monitor: BullFrog AI and Acrivon Therapeutics”

US Weekly IPO and SPAC Monitor: Biotech Acrivon Therapeutics and Online Games Developer Snail

There are two deals due to price in the week ahead, Precision oncology biotech Acrivon Therapeutics (ACRV) plans to raise $100 million and holdover Intensity Therapeutics (INTS) plans to raise $10 million  Online games developer Snail is also expected to Price. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors. The dismal IPO market continued with no new IPO pricings last week in fact … Continue reading “US Weekly IPO and SPAC Monitor: Biotech Acrivon Therapeutics and Online Games Developer Snail”